Investigational drug · Phase 3
TPX-115
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Partial Thickness Rotator Cuff Tear, Partial Thickness Rotator Cuff Tears.
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "TPX-115"
First trial start
2024
Apr 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TPX-115", any sponsor or status.
Conditions studied
As listed on its trial records.
- Partial Thickness Rotator Cuff Tear
- Partial Thickness Rotator Cuff Tears
Largest trials
Live from ClinicalTrials.gov: studies naming "TPX-115" as an intervention, largest first.
- A Phase 2b/3 Study of TPX-115 on Partial-thickness Rotator Cuff TearPivotal-lookingRecruiting
Tego Science, Inc.Industry
NCT06414005 · 166 participants (planned) · Start Apr 15, 2024 · Primary completion Jun 30, 2026
Drug: TPX-115 · For: Partial Thickness Rotator Cuff Tear
Sites: Seongnam-si, South Korea; Seoul, South Korea
Tego Science, Inc.Industry
NCT07219654 · 60 participants (planned) · Start Jun 9, 2026 · Primary completion May 2027
Drug: TPX-115; Saline · For: Partial Thickness Rotator Cuff Tears
Sites: La Mesa, California; Deerfield Beach, Florida; Chicago, Illinois
Tego Science, Inc.Industry
NCT04470167 · 49 participants · Start Oct 26, 2020 · Primary completion Feb 17, 2022
Drug: TPX-115 · For: Rotator Cuff Injuries
Sites: Seongnam-si, South Korea; Seoul, South Korea
- Safety Study of TPX-121 on Nasolabial FoldsActive, not recruiting
Tego Science, Inc.Industry
NCT06533540 · 18 participants (planned) · Start Dec 11, 2024 · Primary completion Mar 2026
Drug: TPX-115(allogeneic fibroblasts) · For: Nasolabial Fold, Hypoplastic
Sites: Daegu, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.